Shares of P3 Health Partners Inc. more than tripled on Friday, reaching $13.00 by late trading, after the company reported its first-ever quarterly profit and raised its 2026 adjusted EBITDA guidance. The stock, which closed at $4.03 the prior session, touched an intraday high of $14.08, according to market data.
First Quarterly Profit
For the first quarter ended March 31, 2026, P3 posted net income of $3.0 million, compared with a net loss of $44.2 million in the same period a year earlier. Revenue rose 4% to $386 million, even as at-risk membership fell 10% to approximately 106,000, a decline the company attributed to intentional network and payer rationalization. Total lives under management stood at about 135,000, with 29,000 under service arrangements.
Adjusted EBITDA and One-Time Benefits
Adjusted EBITDA, a non-GAAP measure that excludes interest, taxes, depreciation, amortization, and certain other items, came in at $25.8 million, compared with a loss of $22.2 million in the prior-year quarter. However, CFO Leif Pedersen noted that roughly $17 million of the quarter's benefit stemmed from favorable prior-year development and payer settlements, with about 65% tied to reserve development and 35% to settlements. Excluding those one-time items, underlying adjusted EBITDA was $8 million.
Medical Margin Improvement
Medical margin, the amount left after deducting medical claims from capitation revenue, jumped to $73.7 million from $17.2 million a year earlier. The company said per-member Medicare Advantage funding improved approximately 15% year-over-year, aided by rate progression, contract changes, and better documentation of patient illness burden.
Raised 2026 Outlook
P3 raised its full-year 2026 adjusted EBITDA forecast to a range of $20 million to $60 million, with a midpoint of $40 million. CEO Dr. Aric Coffman called the quarter a meaningful turning point, reflecting two years of contract restructuring, network concentration, and operational redesign.
Industry Context
The results come amid investor focus on whether Medicare Advantage costs are stabilizing. Reuters reported this week that U.S. insurers showed stronger first-quarter results, but analysts cautioned that the second quarter would provide a clearer picture of claims trends after early-year distortions. Other value-based care companies, such as Agilon Health and Privia Health, also reported improved adjusted EBITDA in the first quarter.
Balance Sheet Concerns
Despite the positive earnings, P3's balance sheet remains a concern. The company's 10-Q filing indicated substantial doubt about its ability to continue as a going concern within one year and warned it may need additional debt or equity financing if cash flow is insufficient to fund operations. The filing also revealed a working capital deficit of $353.3 million and a stockholders' deficit of $143.5 million as of March 31.
Recent Financing Steps
In an April 27 debt exchange, approximately $252.5 million of unsecured promissory notes were converted into preferred stock. The company also agreed to issue up to $70 million of preferred stock-and-warrant units, with $30 million already sold by April 30. These steps are intended to strengthen the company's financial position.
Outlook and Risks
The key test for P3 will be its ability to control medical costs throughout the remainder of the year, not just during a strong first quarter. CFO Pedersen noted that results within the new guidance range depend on cost-trend development and the execution of medical-cost initiatives. After Friday's sharp stock move, there is less room for error.